Azora Therapeutics

Azora Therapeutics is a private, pre-revenue biotech leveraging the aryl hydrocarbon receptor (AhR) pathway to develop localized small molecule therapies for inflammatory diseases. The company has a clinical-stage program, evidenced by a published Phase 1b study in ulcerative colitis, and is built by a team with significant prior drug development experience. Its strategy focuses on addressing serious conditions like hidradenitis suppurativa and ulcerative colitis by targeting a fundamental immune regulatory mechanism with potential for improved safety and efficacy.

Development of best-in-class, locally administered small molecule agonists of the aryl hydrocarbon receptor (AhR) to rebalance immune response at barrier sites.

Azora competes in the crowded autoimmune/inflammatory space against large biopharma companies and numerous biotechs. Its differentiation hinges on the novelty of localized AhR agonism, which, if clinically validated, could offer a favorable safety profile versus systemic immunosuppressants. Competitors include developers of other novel small molecules, biologics targeting specific cytokines, and JAK inhibitors.